Literature DB >> 9352986

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).

R P Byington1, M E Miller, D Herrington, W Riley, B Pitt, C D Furberg, D B Hunninghake, G B Mancini.   

Abstract

The Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial is the first angiographic clinical trial to be designed to test whether an agent can slow or even reverse the progression of early coronary atherosclerosis in patients with documented disease. In addition, a subset of patients are undergoing carotid ultrasound examinations, providing a unique opportunity to assess and correlate disease progression in 2 arterial beds.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9352986     DOI： 10.1016/s0002-9149(97)00611-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  3 in total

1.  Association of increased carotid intima-media thickness with the extent of coronary artery disease.

Authors:  A Kablak-Ziembicka; W Tracz; T Przewlocki; P Pieniazek; A Sokolowski; M Konieczynska
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

2.  Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Authors:  Peter Willeit; Lena Tschiderer; Michael J Sweeting; Simon G Thompson; Matthias W Lorenz; Elias Allara; Kathrin Reuber; Lisa Seekircher; Lu Gao; Ximing Liao; Eva Lonn; Hertzel C Gerstein; Salim Yusuf; Frank P Brouwers; Folkert W Asselbergs; Wiek van Gilst; Sigmund A Anderssen; Diederick E Grobbee; John J P Kastelein; Frank L J Visseren; George Ntaios; Apostolos I Hatzitolios; Christos Savopoulos; Pythia T Nieuwkerk; Erik Stroes; Matthew Walters; Peter Higgins; Jesse Dawson; Paolo Gresele; Giuseppe Guglielmini; Rino Migliacci; Marat Ezhov; Maya Safarova; Tatyana Balakhonova; Eiichi Sato; Mayuko Amaha; Tsukasa Nakamura; Kostas Kapellas; Lisa M Jamieson; Michael Skilton; James A Blumenthal; Alan Hinderliter; Andrew Sherwood; Patrick J Smith; Michiel A van Agtmael; Peter Reiss; Marit G A van Vonderen; Stefan Kiechl; Gerhard Klingenschmid; Matthias Sitzer; Coen D A Stehouwer; Heiko Uthoff; Zhi-Yong Zou; Ana R Cunha; Mario F Neves; Miles D Witham; Hyun-Woong Park; Moo-Sik Lee; Jang-Ho Bae; Enrique Bernal; Kristian Wachtell; Sverre E Kjeldsen; Michael H Olsen; David Preiss; Naveed Sattar; Edith Beishuizen; Menno V Huisman; Mark A Espeland; Caroline Schmidt; Stefan Agewall; Ercan Ok; Gülay Aşçi; Eric de Groot; Muriel P C Grooteman; Peter J Blankestijn; Michiel L Bots
Journal:  Circulation       Date:  2020-06-17       Impact factor: 29.690

3.  Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.

Authors:  Emma Copland; Dexter Canoy; Milad Nazarzadeh; Zeinab Bidel; Rema Ramakrishnan; Mark Woodward; John Chalmers; Koon K Teo; Carl J Pepine; Barry R Davis; Sverre Kjeldsen; Johan Sundström; Kazem Rahimi
Journal:  Lancet Oncol       Date:  2021-04       Impact factor: 41.316
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.